NASDAQ:IFRX - InflaRx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.17
  • Forecasted Upside: 89.27 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.90
▲ +0.34 (6.12%)
1 month | 3 months | 12 months
Get New InflaRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IFRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IFRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.17
▲ +89.27% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for InflaRx in the last 3 months. The average price target is $11.17, with a high forecast of $19.00 and a low forecast of $7.00. The average price target represents a 89.27% upside from the last price of $5.90.
Buy
The current consensus among 7 investment analysts is to buy stock in InflaRx. This rating has held steady since May 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
7/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021HC WainwrightReiterated RatingBuyMedium
i
Rating by E. White at HC Wainwright
1/7/2021HC WainwrightBoost Price TargetBuy$11.00 ➝ $12.00N/A
i
Rating by E. White at HC Wainwright
11/6/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$7.00 ➝ $10.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
10/30/2020Lifesci CapitalReiterated RatingMarket PerformLow
i
Rating by S. Slutsky at Lifesci Capital
10/8/2020HC WainwrightInitiated CoverageBuy$11.00Medium
i
Rating by E. White at HC Wainwright
9/14/2020Ci CapitalReiterated RatingHold$7.00High
i
7/31/2020Raymond JamesLower Price TargetOutperform$20.00 ➝ $19.00High
i
Rating by Steven Seedhouse at Raymond James
6/17/2020Raymond JamesReiterated RatingBuyMedium
i
Rating by Steven Seedhouse at Raymond James
6/16/2020BTIG ResearchInitiated CoverageBuy$12.00High
i
5/28/2020Ci CapitalReiterated RatingHold$7.00Medium
i
5/21/2020BMO Capital MarketsBoost Price TargetMarket Perform$4.00 ➝ $7.00Medium
i
5/21/2020Raymond JamesBoost Price TargetOutperform$10.00 ➝ $20.00High
i
5/7/2020SVB LeerinkBoost Price TargetHold$4.00 ➝ $7.00Low
i
4/29/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$10.00High
i
7/19/2019Raymond JamesReiterated RatingHoldN/A
i
Rating by Steven Seedhouse at Raymond James
6/5/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by J. Schwartz at SVB Leerink LLC
6/5/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
Rating by Steven Seedhouse at Raymond James
6/5/2019Credit Suisse GroupDowngradeOutperform ➝ UnderperformHigh
i
6/5/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$5.00High
i
6/5/2019SunTrust BanksDowngradeBuy ➝ Hold$55.00 ➝ $5.00High
i
6/5/2019Robert W. BairdDowngradeOutperform ➝ Neutral$58.00 ➝ $6.00High
i
6/5/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$67.00 ➝ $9.00High
i
6/5/2019GuggenheimDowngradeBuy ➝ Neutral$65.00 ➝ $6.00High
i
Rating by Yatin Suneja at Guggenheim
5/24/2019Raymond JamesSet Price TargetBuy$44.00Medium
i
Rating by Steven Seedhouse at Raymond James
4/24/2019BMO Capital MarketsBoost Price TargetOutperform$64.00High
i
3/29/2019Robert W. BairdLower Price TargetOutperform ➝ Outperform$62.00 ➝ $58.00High
i
2/22/2019GuggenheimInitiated CoverageBuy$65.00Low
i
2/5/2019JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Top Pick$42.00 ➝ $65.00High
i
1/28/2019Robert W. BairdInitiated CoverageOutperform$62.00High
i
12/10/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$47.00Low
i
7/13/2018BMO Capital MarketsInitiated CoverageOutperform$45.00Medium
i
Rating by Matthew Luchini at BMO Capital Markets
6/28/2018Raymond JamesInitiated CoverageOutperform$44.00High
i
6/28/2018SunTrust BanksInitiated CoverageBuy$55.00High
i
5/18/2018SVB LeerinkReiterated RatingOutperform$42.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
4/2/2018SVB LeerinkBoost Price TargetOutperform$31.00 ➝ $36.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
2/8/2018B. RileyInitiated CoverageBuy ➝ Buy$40.00Low
i
Rating by M. Kumar at B. Riley
12/4/2017BMO Capital MarketsInitiated CoverageOutperform$31.00High
i
12/4/2017SVB LeerinkInitiated CoverageOutperform$31.00High
i
Rating by J. Schwartz at SVB Leerink LLC
12/4/2017JPMorgan Chase & Co.Initiated CoverageOverweight$30.00High
i
(Data available from 1/20/2016 forward)
InflaRx logo
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Read More

Today's Range

Now: $5.90
$5.71
$6.07

50 Day Range

MA: $5.11
$3.94
$6.31

52 Week Range

Now: $5.90
$2.52
$9.70

Volume

285,735 shs

Average Volume

482,344 shs

Market Capitalization

$154.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of InflaRx?

The following sell-side analysts have issued research reports on InflaRx in the last year: BMO Capital Markets, BTIG Research, Ci Capital, HC Wainwright, Lifesci Capital, Raymond James, SVB Leerink LLC, and Zacks Investment Research.

What is the current price target for InflaRx?

6 Wall Street analysts have set twelve-month price targets for InflaRx in the last year. Their average twelve-month price target is $11.17, suggesting a possible upside of 89.3%. Raymond James has the highest price target set, predicting IFRX will reach $19.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $7.00 for InflaRx in the next year.

What is the current consensus analyst rating for InflaRx?

InflaRx currently has 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IFRX will outperform the market and that investors should add to their positions of InflaRx.

What other companies compete with InflaRx?

How do I contact InflaRx's investor relations team?

InflaRx's physical mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company's listed phone number is 49-36-4150-8180 and its investor relations email address is jordan.zwick@inflarx.de. The official website for InflaRx is www.inflarx.de.